Cargando…

18F‐fluoro‐2‐deoxy‐2‐d‐glucose PET‐CT (FDG PET‐CT) in staging of high‐risk renal and urothelial bladder cancers (COPPER‐T) trial protocol

BACKGROUND AND STUDY DESIGN: Role of (18)F‐fluoro‐2‐deoxy‐2‐d‐glucose positron emission tomography‐computed tomography (FDG PET‐CT) in evaluation of renal cell cancers (RCC) and urinary bladder cancers is not standardized, and the COPPER‐T trial, which is a single centre prospective randomized study...

Descripción completa

Detalles Bibliográficos
Autores principales: Jena, Rahul, Bhargava, Priyank, Tripathi, Shashank, Taywade, Sameer, Yadav, Taruna, Sandhu, Arjun Singh, Singh, Mahendra, Navriya, Shiv Charan, Bhirud, Deepak Prakash, Aggarwal, Amit, Choudhary, Gautam Ram
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10560619/
https://www.ncbi.nlm.nih.gov/pubmed/37818027
http://dx.doi.org/10.1002/bco2.246
_version_ 1785117763425009664
author Jena, Rahul
Bhargava, Priyank
Tripathi, Shashank
Taywade, Sameer
Yadav, Taruna
Sandhu, Arjun Singh
Singh, Mahendra
Navriya, Shiv Charan
Bhirud, Deepak Prakash
Aggarwal, Amit
Choudhary, Gautam Ram
author_facet Jena, Rahul
Bhargava, Priyank
Tripathi, Shashank
Taywade, Sameer
Yadav, Taruna
Sandhu, Arjun Singh
Singh, Mahendra
Navriya, Shiv Charan
Bhirud, Deepak Prakash
Aggarwal, Amit
Choudhary, Gautam Ram
author_sort Jena, Rahul
collection PubMed
description BACKGROUND AND STUDY DESIGN: Role of (18)F‐fluoro‐2‐deoxy‐2‐d‐glucose positron emission tomography‐computed tomography (FDG PET‐CT) in evaluation of renal cell cancers (RCC) and urinary bladder cancers is not standardized, and the COPPER‐T trial, which is a single centre prospective randomized study, was designed to compare it with conventional imaging for staging of clinically localized high risk RCC and urinary bladder carcinoma (Stage T2 and above). PATIENTS AND METHODS: There will be two subgroups of patients: RCC and urinary bladder carcinoma. In each of these, the patients will be randomized to either Arm A or Arm B. In each of the arms, each patient will be subjected to diagnostic imaging by FDG PET‐CT. The CT scan will be a contrast‐enhanced scan like that in conventional staging. A radiologist and nuclear medicine specialist will report the scan independently. The radiologist will not have access to the PET scan sequences and will only review the contrast‐enhanced computed tomography (CECT) images. In Arm A, the report of the conventional imaging modality, that is, CECT and bone scan if done, will be reviewed first by the clinician, and based on this report, a management plan will be made. Then, the PET‐CT report will be reviewed, and change in the management plan will be noted. New findings or equivocal findings if any in the PET‐CT report would be noted. In Arm B, the report of the PET‐CT report will be reviewed first by the clinicians, and a management plan will be made. Then, the CECT and/or bone scan reports will be reviewed, and any change in the management plan will be noted. OUTCOME AND SIGNIFICANCE: Final analysis of the data after completion of the trial will help in clarifying the role of FDG PET‐CT in high risk RCC and transitional cell carcinoma (TCC) of the bladder, its diagnostic accuracy compared with conventional imaging and the impact of using it on patient management.
format Online
Article
Text
id pubmed-10560619
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-105606192023-10-10 18F‐fluoro‐2‐deoxy‐2‐d‐glucose PET‐CT (FDG PET‐CT) in staging of high‐risk renal and urothelial bladder cancers (COPPER‐T) trial protocol Jena, Rahul Bhargava, Priyank Tripathi, Shashank Taywade, Sameer Yadav, Taruna Sandhu, Arjun Singh Singh, Mahendra Navriya, Shiv Charan Bhirud, Deepak Prakash Aggarwal, Amit Choudhary, Gautam Ram BJUI Compass Original Articles BACKGROUND AND STUDY DESIGN: Role of (18)F‐fluoro‐2‐deoxy‐2‐d‐glucose positron emission tomography‐computed tomography (FDG PET‐CT) in evaluation of renal cell cancers (RCC) and urinary bladder cancers is not standardized, and the COPPER‐T trial, which is a single centre prospective randomized study, was designed to compare it with conventional imaging for staging of clinically localized high risk RCC and urinary bladder carcinoma (Stage T2 and above). PATIENTS AND METHODS: There will be two subgroups of patients: RCC and urinary bladder carcinoma. In each of these, the patients will be randomized to either Arm A or Arm B. In each of the arms, each patient will be subjected to diagnostic imaging by FDG PET‐CT. The CT scan will be a contrast‐enhanced scan like that in conventional staging. A radiologist and nuclear medicine specialist will report the scan independently. The radiologist will not have access to the PET scan sequences and will only review the contrast‐enhanced computed tomography (CECT) images. In Arm A, the report of the conventional imaging modality, that is, CECT and bone scan if done, will be reviewed first by the clinician, and based on this report, a management plan will be made. Then, the PET‐CT report will be reviewed, and change in the management plan will be noted. New findings or equivocal findings if any in the PET‐CT report would be noted. In Arm B, the report of the PET‐CT report will be reviewed first by the clinicians, and a management plan will be made. Then, the CECT and/or bone scan reports will be reviewed, and any change in the management plan will be noted. OUTCOME AND SIGNIFICANCE: Final analysis of the data after completion of the trial will help in clarifying the role of FDG PET‐CT in high risk RCC and transitional cell carcinoma (TCC) of the bladder, its diagnostic accuracy compared with conventional imaging and the impact of using it on patient management. John Wiley and Sons Inc. 2023-05-10 /pmc/articles/PMC10560619/ /pubmed/37818027 http://dx.doi.org/10.1002/bco2.246 Text en © 2023 The Authors. BJUI Compass published by John Wiley & Sons Ltd on behalf of BJU International Company. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Articles
Jena, Rahul
Bhargava, Priyank
Tripathi, Shashank
Taywade, Sameer
Yadav, Taruna
Sandhu, Arjun Singh
Singh, Mahendra
Navriya, Shiv Charan
Bhirud, Deepak Prakash
Aggarwal, Amit
Choudhary, Gautam Ram
18F‐fluoro‐2‐deoxy‐2‐d‐glucose PET‐CT (FDG PET‐CT) in staging of high‐risk renal and urothelial bladder cancers (COPPER‐T) trial protocol
title 18F‐fluoro‐2‐deoxy‐2‐d‐glucose PET‐CT (FDG PET‐CT) in staging of high‐risk renal and urothelial bladder cancers (COPPER‐T) trial protocol
title_full 18F‐fluoro‐2‐deoxy‐2‐d‐glucose PET‐CT (FDG PET‐CT) in staging of high‐risk renal and urothelial bladder cancers (COPPER‐T) trial protocol
title_fullStr 18F‐fluoro‐2‐deoxy‐2‐d‐glucose PET‐CT (FDG PET‐CT) in staging of high‐risk renal and urothelial bladder cancers (COPPER‐T) trial protocol
title_full_unstemmed 18F‐fluoro‐2‐deoxy‐2‐d‐glucose PET‐CT (FDG PET‐CT) in staging of high‐risk renal and urothelial bladder cancers (COPPER‐T) trial protocol
title_short 18F‐fluoro‐2‐deoxy‐2‐d‐glucose PET‐CT (FDG PET‐CT) in staging of high‐risk renal and urothelial bladder cancers (COPPER‐T) trial protocol
title_sort 18f‐fluoro‐2‐deoxy‐2‐d‐glucose pet‐ct (fdg pet‐ct) in staging of high‐risk renal and urothelial bladder cancers (copper‐t) trial protocol
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10560619/
https://www.ncbi.nlm.nih.gov/pubmed/37818027
http://dx.doi.org/10.1002/bco2.246
work_keys_str_mv AT jenarahul 18ffluoro2deoxy2dglucosepetctfdgpetctinstagingofhighriskrenalandurothelialbladdercancerscopperttrialprotocol
AT bhargavapriyank 18ffluoro2deoxy2dglucosepetctfdgpetctinstagingofhighriskrenalandurothelialbladdercancerscopperttrialprotocol
AT tripathishashank 18ffluoro2deoxy2dglucosepetctfdgpetctinstagingofhighriskrenalandurothelialbladdercancerscopperttrialprotocol
AT taywadesameer 18ffluoro2deoxy2dglucosepetctfdgpetctinstagingofhighriskrenalandurothelialbladdercancerscopperttrialprotocol
AT yadavtaruna 18ffluoro2deoxy2dglucosepetctfdgpetctinstagingofhighriskrenalandurothelialbladdercancerscopperttrialprotocol
AT sandhuarjunsingh 18ffluoro2deoxy2dglucosepetctfdgpetctinstagingofhighriskrenalandurothelialbladdercancerscopperttrialprotocol
AT singhmahendra 18ffluoro2deoxy2dglucosepetctfdgpetctinstagingofhighriskrenalandurothelialbladdercancerscopperttrialprotocol
AT navriyashivcharan 18ffluoro2deoxy2dglucosepetctfdgpetctinstagingofhighriskrenalandurothelialbladdercancerscopperttrialprotocol
AT bhiruddeepakprakash 18ffluoro2deoxy2dglucosepetctfdgpetctinstagingofhighriskrenalandurothelialbladdercancerscopperttrialprotocol
AT aggarwalamit 18ffluoro2deoxy2dglucosepetctfdgpetctinstagingofhighriskrenalandurothelialbladdercancerscopperttrialprotocol
AT choudharygautamram 18ffluoro2deoxy2dglucosepetctfdgpetctinstagingofhighriskrenalandurothelialbladdercancerscopperttrialprotocol